Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Intermittent Explosive Disorder: early-phase trial registry
3 of 4 indexed Intermittent Explosive Disorder trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 3 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Intermittent Explosive Disorder: 4 US clinical trials tracked, 3 recruiting.
Intermittent Explosive Disorder is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Ohio State University, running 3 of these trials.
Enrollment posture brief
Registry condition intermittent-explosive-disorder
OPEN 3 | RECR 75% | LATE 0 | EARLY 4 | RANK #4115 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Activity, Motor (75% recruiting · 8 trials)
Intermittent Explosive Disorder lists 3 open slots (75% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Intermittent Explosive Disorder on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Intermittent Explosive Disorder is recruiting above its size-band peers.
3 of 4 indexed trials (75%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
Neural Correlates During Alcohol Intoxication
Ohio State University
NCT06118580
Effect of Nitrous Oxide on Aggression.
Ohio State University
NCT06118567
Pimavanserin and Aggression and Social Cognition.
Ohio State University
NCT05895513
A Comparison of Fluoxetine and Divalproex for the Treatment of Intermittent Explosive Disorder
University of Chicago
NCT00078754
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Intermittent Explosive Disorder records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Intermittent Explosive Disorder trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Intermittent Explosive Disorder page
4 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Intermittent Explosive Disorder trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Ohio State University sponsors the most Intermittent Explosive Disorder trials on record, review their full trial history before evaluating a specific study. See Ohio State University's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Intermittent Explosive Disorder condition card totals 4 registered trials; most-linked intervention Placebo; top US site state Ohio. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.